By otakuyassine3@gmail.com 
Teacher Retirement System of Texas increased its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 60.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 73,392 shares of the company’s stock after purchasing an additional 27,511 shares during the period. Teacher Retirement System of Texas’ holdings in Recursion Pharmaceuticals were worth $496,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in RXRX. Privium Fund Management B.V. boosted its position in shares of Recursion Pharmaceuticals by 52.6% during the fourth quarter. Privium Fund Management B.V. now owns 119,000 shares of the company’s stock worth $804,000 after buying an additional 41,000 shares during the period. Platinum Investment Management Ltd. lifted its stake in Recursion Pharmaceuticals by 293.9% during the 4th quarter. Platinum Investment Management Ltd. now owns 733,011 shares of the company’s stock worth $4,955,000 after acquiring an additional 546,929 shares in the last quarter. Xponance Inc. boosted its holdings in Recursion Pharmaceuticals by 22.2% during the 4th quarter. Xponance Inc. now owns 19,163 shares of the company’s stock valued at $130,000 after acquiring an additional 3,480 shares during the period. Signaturefd LLC grew its position in Recursion Pharmaceuticals by 45.0% in the 4th quarter. Signaturefd LLC now owns 11,769 shares of the company’s stock valued at $80,000 after acquiring an additional 3,651 shares in the last quarter. Finally, Cibc World Markets Corp purchased a new stake in Recursion Pharmaceuticals during the fourth quarter worth about $157,000. Institutional investors and hedge funds own 89.06% of the company’s stock.
Analyst Upgrades and Downgrades
Several research analysts have recently commented on the stock. Leerink Partners lowered their price objective on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a research note on Friday, February 28th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 8th. Finally, Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $8.25.
Get Our Latest Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Trading Down 9.0 %
NASDAQ RXRX opened at $5.29 on Tuesday. Recursion Pharmaceuticals, Inc. has a 52 week low of $5.19 and a 52 week high of $12.36. The firm has a 50 day moving average of $7.42 and a two-hundred day moving average of $7.00. The stock has a market capitalization of $2.13 billion, a PE ratio of -3.46 and a beta of 0.85. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last posted its earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The business had revenue of $4.60 million during the quarter, compared to analysts’ expectations of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business’s quarterly revenue was down 57.8% compared to the same quarter last year. During the same period last year, the company earned ($0.42) EPS. As a group, research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
Want to see what other hedge funds are holding RXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report).
Receive News & Ratings for Recursion Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.